ES2184791T3 - Peptidos y sus utilizaciones contra la psoriasis. - Google Patents

Peptidos y sus utilizaciones contra la psoriasis.

Info

Publication number
ES2184791T3
ES2184791T3 ES95909258T ES95909258T ES2184791T3 ES 2184791 T3 ES2184791 T3 ES 2184791T3 ES 95909258 T ES95909258 T ES 95909258T ES 95909258 T ES95909258 T ES 95909258T ES 2184791 T3 ES2184791 T3 ES 2184791T3
Authority
ES
Spain
Prior art keywords
psoriasis
cell
peptides
peptide
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95909258T
Other languages
English (en)
Inventor
Jennie C C Chang
Steven W Brostoff
Dennis J Carlo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Response Corp
Original Assignee
Immune Response Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp filed Critical Immune Response Corp
Application granted granted Critical
Publication of ES2184791T3 publication Critical patent/ES2184791T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)

Abstract

ESTA INVENCION SE REFIERE A METODOS DE PREVENCION O REDUCCION DE LA GRAVEDAD DE LA PSOSIASIS.EN UNA VERSION, EL METODO IMPLICA LA ADMINISTRACION AL INDIVIDUO DE UN PEPTIDO QUE TENGA SUBSTANCIALMENTE LA SECUENCIA DE UNA SECUENCIA NO CONSERVADA DE UNA CELULA T RECEPTORA QUE ESTA PRESENTE EN LA SUPERFICIE DE LA REGION DE LAS CELULAS T QUE ES MEDIADORA DE LA PSORIASIS O UN FRAGMENTO DE LAS MISMAS, EN DONDE EL PEPTIDO O EL FRAGMENTO ES CAPAZ DE CAUSAR UN EFECTO EN EL SISTEMA INMUNE PARA REGULAR LAS CELULAS T. EN PARTICULAR, LA CELULA T RECEPTORA TIENE LA REGION V{BE}, V{BE}3, V{BE}13.1 O V{BE}17. EN OTRA VERSION, EL METODO IMPLICA UNA TERAPIA GENETICA. LA INVENCION TAMBIEN TRATA DE METODOS PARA EL DIAGNOSTICO DE LA PSORIASIS MEDIANTE LA DETERMINACION DE LA PRESENCIA PREDOMINANTE DE LAS CELULAS T RECEPTORAS DE PSORIASIS.
ES95909258T 1994-01-14 1995-01-13 Peptidos y sus utilizaciones contra la psoriasis. Expired - Lifetime ES2184791T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/182,967 US6413516B1 (en) 1989-03-21 1994-01-14 Peptides and methods against psoriasis

Publications (1)

Publication Number Publication Date
ES2184791T3 true ES2184791T3 (es) 2003-04-16

Family

ID=22670842

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95909258T Expired - Lifetime ES2184791T3 (es) 1994-01-14 1995-01-13 Peptidos y sus utilizaciones contra la psoriasis.

Country Status (14)

Country Link
US (1) US6413516B1 (es)
EP (1) EP0738281B1 (es)
JP (2) JPH09508112A (es)
CN (1) CN1138865A (es)
AT (1) ATE227738T1 (es)
BR (1) BR9506511A (es)
CA (1) CA2179280A1 (es)
DE (1) DE69528817T2 (es)
ES (1) ES2184791T3 (es)
FI (1) FI962836A0 (es)
MX (1) MX9602473A (es)
NO (1) NO962943L (es)
NZ (1) NZ279987A (es)
WO (1) WO1995019375A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
JP2009266963A (ja) * 2008-04-23 2009-11-12 Sumitomo Electric Ind Ltd 窒化物系発光素子、及び半導体発光素子を製造する方法
CA3194968A1 (en) * 2020-09-11 2022-03-17 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
WO2023111695A1 (en) 2021-12-16 2023-06-22 Ramakrishna Reddy Isanaka A stable anti-angiogenic and anti-inflammatory pharmaceutical formulation and pharmaceutical combination for treatment and prevention of psoriasis
CN116466095B (zh) * 2023-06-15 2023-09-01 朗肽生物制药股份有限公司 一种多肽及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584209T2 (de) * 1984-03-01 1995-05-04 Univ Leland Stanford Junior T-zellenrezeptor, spezifisch für antigenpolypeptide und verwandte polynukleotide.
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
EP0552142B2 (en) * 1989-07-19 2003-12-17 Corporation Connetics T cell receptor peptides as therapeutics for autoimmune and malignant disease
CA2072356A1 (en) * 1989-12-29 1991-06-30 James L. Urban Diagnosis and treatment of diseases
JPH06511241A (ja) 1991-09-23 1994-12-15 ジェネンテク，インコーポレイテッド 自己免疫疾患の診断および治療
CA2126686A1 (en) * 1991-12-24 1993-07-08 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations

Also Published As

Publication number Publication date
AU1728295A (en) 1995-08-01
CN1138865A (zh) 1996-12-25
NO962943D0 (no) 1996-07-12
FI962836A (fi) 1996-07-12
NZ279987A (en) 1999-09-29
US6413516B1 (en) 2002-07-02
MX9602473A (es) 1997-05-31
WO1995019375A1 (en) 1995-07-20
DE69528817D1 (de) 2002-12-19
DE69528817T2 (de) 2003-09-11
EP0738281B1 (en) 2002-11-13
ATE227738T1 (de) 2002-11-15
NO962943L (no) 1996-09-13
FI962836A0 (fi) 1996-07-12
CA2179280A1 (en) 1995-07-20
AU697910B2 (en) 1998-10-22
JPH09508112A (ja) 1997-08-19
EP0738281A1 (en) 1996-10-23
BR9506511A (pt) 1997-09-09
JP2001288108A (ja) 2001-10-16

Similar Documents

Publication Publication Date Title
AU3649397A (en) Precise efficacy assay methods for active agents including chemotherapeutic agents
WO1998002546A3 (en) Dna immunization against chlamydia infection
DE69637147D1 (de) Transportproteine und deren verwendungen
ES2111710T3 (es) Proteasas que inhiben y desprenden el biofilm.
ITRM920590A1 (it) Sistema per la realizzazione distrutture in fibra di carbonio, e procedimento per detto, particolarmente idoneo per applicazioni aeronautiche.
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
ES2143641T3 (es) Expresion en superficie de una enzima en la terapia genica a base de promedicamentos.
DE3586697D1 (en) Aktive thymopentin-analoga.
AU4559300A (en) Use of phyllanthus for targeted stimulation of the immune system
ES2376225T3 (es) Genes de elongasa y usos de los mismos.
BR9809284A (pt) Construto e processo para expressão de polinucleotìdeo em altos nìveis
ES2184791T3 (es) Peptidos y sus utilizaciones contra la psoriasis.
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
AU5104198A (en) Use of conjugated linoleic acid to enhance natural killer lymphocyte function
WO1999025878A3 (en) Methods for modulating and identifying cellular senescence
ES2171465T3 (es) Inhibidor de la esterasa de c1 para reducir lesiones de miocardio durante un infarto de miocardio agudo.
AU1795783A (en) New polypeptide from thymus glands
EP0751780A4 (en) METHOD FOR ISOLATING CDA-PRESENTED ANTIGENS, CD1-PRESENTED ANTIGEN-CONTAINING VACCINES, AND CELL LINES USED IN Said PROCEDURE
WO1997042347A3 (en) 5-lipoxygenase gene polymorphisms and their use in classifying patients
ES2089177T3 (es) Nuevos peptidos inhibidores.
CO4440441A1 (es) Enzima dextranasa, metodo para su produccion y adn que la codifica
IT1317849B1 (it) Mezzi e metodi per l'espressione di proteine omologhe ed eterologhe inceppi di rhodococcus.
IL139303A0 (en) Treatment of arthritis and other similar conditions
PT837940E (pt) Novos factores de secrecao para microorganismos gram-positivos, genes que os codificam e metodos para a sia utilizacao
MX9304526A (es) Sistema local de evacuacion de material de desecho biotoxico.